Value proposition

Improving cancer outcomes by overcoming hypoxia.

StimOxyGen is a proprietary and world-leading innovative approach to address the global challenge of tumour hypoxia.

Hypoxia, or lack of oxygen, is a common characteristic of solid tumours that contributes to the failure of many types of cancer treatment, particularly radiotherapy which relies on oxygen for maximum efficacy.

We can solve this longstanding major unmet clinical need by fueling tumours with oxygen to maximise therapeutic effects of radiotherapy.

nanotechnology, cancer research, hypoxia, and pancreatic cancer